Alternative Data for Nurix Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 637 | Sign up | Sign up | Sign up |
| X Followers | 672 | Sign up | Sign up | Sign up |
| X Mentions | 13 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 353 | Sign up | Sign up | Sign up |
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
| Price | $15.90 |
| Target Price | Sign up |
| Volume | 715,997 |
| Market Cap | $1.55B |
| Year Range | $8.24 - $21.47 |
| Dividend Yield | 0% |
| Analyst Rating | 93% buy |
| Industry | Biotechnology |
In the news
 |
H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX)January 30 - Yahoo Entertainment |
 |
Nurix Therapeutics price target raised by $1 at H.C. Wainwright, here's whyJanuary 29 - Thefly.com |
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate UpdateJanuary 28 - GlobeNewswire |
|
 |
Nurix Therapeutics: Why This Company Could Double In Value?January 15 - SeekingAlpha |
 |
Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 12 - SeekingAlpha |
|
Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 12 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 7.9M | 5M | 2.9M | -86M | -81M | -1.030 |
| Q2 '25 | 44M | 78M | -34M | -43M | -46M | -0.520 |
| Q1 '25 | 18M | 70M | -51M | -56M | -61M | -0.670 |
| Q4 '24 | 13M | 67M | -54M | -59M | -63M | -0.750 |
| Q3 '24 | 13M | 55M | -43M | -49M | -52M | -0.670 |
Insider Transactions View All
| Ring Christine filed to sell 34,601 shares at $15.4. March 2 '26 |
| Ring Christine filed to sell 42,749 shares at $16.7. February 9 '26 |
| Hansen Gwenn filed to sell 83,672 shares at $17.4. January 30 '26 |
| Ring Christine filed to sell 57,010 shares at $17.4. January 30 '26 |
| Van Houte Hans filed to sell 45,427 shares at $17.4. January 30 '26 |
Similar companies
Read more about Nurix Therapeutics (NRIX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Nurix Therapeutics
The Market Cap of Nurix Therapeutics is $1.55B.
Currently, the price of one share of Nurix Therapeutics stock is $15.90.
The NRIX stock price chart above provides a comprehensive visual representation of Nurix Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Nurix Therapeutics shares. Our platform offers an up-to-date NRIX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Nurix Therapeutics (NRIX) does not offer dividends to its shareholders. Investors interested in Nurix Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Nurix Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
